Sun W, Haller D G
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania 19104, USA.
Drugs. 2001;61(11):1545-51. doi: 10.2165/00003495-200161110-00002.
Gastric cancer is one of the most common cancers in the world. The prognosis of the disease is poor, with only 40% of patients eligible to undergo potentially curative surgery. Even for those patients who undergo a complete resection, the rate of recurrence is very high. Extensive studies of multidisciplinary adjuvant treatment have been conducted seeking to improve the cure rates in the past two decades. The benefit of D2 dissection is still controversial and is undergoing prospective evaluation. Preliminary results from the United States Gastrointestinal Intergroup study, a well designed trial, have shown overall survival benefit of postoperative chemoradiation therapy. Neoadjuvant chemotherapy or chemoradiation is under active study in order to increase the number of patients to undergo potential curative surgery. Although many chemotherapy regimens have been developed recently, only modest clinical efficacy has been demonstrated for advanced metastatic disease. So far, there is no single regimen considered to be standard.
胃癌是世界上最常见的癌症之一。该疾病的预后较差，只有40%的患者有资格接受可能治愈性的手术。即使是那些接受了完整切除的患者，复发率也非常高。在过去二十年中，已经进行了广泛的多学科辅助治疗研究，以寻求提高治愈率。D2根治术的益处仍存在争议，正在进行前瞻性评估。美国胃肠肿瘤协作组研究这一精心设计的试验的初步结果显示，术后放化疗有总体生存益处。新辅助化疗或放化疗正在积极研究中，以增加有资格接受潜在治愈性手术的患者数量。尽管最近已经开发了许多化疗方案，但对于晚期转移性疾病仅显示出适度的临床疗效。到目前为止，没有一种方案被认为是标准方案。
